TENAYA THERAPEUTICS INC (TNYA)

US87990A1060 - Common Stock

2.41  +0.47 (+24.23%)

After market: 2.43 +0.02 (+0.83%)

Fundamental Rating

2

TNYA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 564 industry peers in the Biotechnology industry. TNYA has a great financial health rating, but its profitability evaluates not so good. TNYA is valued expensive and it does not seem to be growing.



0

1. Profitability

1.1 Basic Checks

In the past year TNYA has reported negative net income.
TNYA had a negative operating cash flow in the past year.
TNYA had negative earnings in each of the past 5 years.
TNYA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

TNYA has a Return On Assets of -73.99%. This is in the lower half of the industry: TNYA underperforms 69.88% of its industry peers.
The Return On Equity of TNYA (-90.10%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -73.99%
ROE -90.1%
ROIC N/A
ROA(3y)-46.75%
ROA(5y)-47.04%
ROE(3y)-55.31%
ROE(5y)-56.6%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

TNYA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

7

2. Health

2.1 Basic Checks

The number of shares outstanding for TNYA has been increased compared to 1 year ago.
TNYA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

TNYA has an Altman-Z score of -2.76. This is a bad value and indicates that TNYA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.76, TNYA perfoms like the industry average, outperforming 47.42% of the companies in the same industry.
TNYA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.76
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

TNYA has a Current Ratio of 6.28. This indicates that TNYA is financially healthy and has no problem in meeting its short term obligations.
TNYA's Current ratio of 6.28 is fine compared to the rest of the industry. TNYA outperforms 62.57% of its industry peers.
A Quick Ratio of 6.28 indicates that TNYA has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.28, TNYA is doing good in the industry, outperforming 62.75% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.28
Quick Ratio 6.28

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 31.39% over the past year.
EPS 1Y (TTM)31.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 35.69% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y8.92%
EPS Next 2Y2.37%
EPS Next 3Y2.07%
EPS Next 5Y35.69%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TNYA. In the last year negative earnings were reported.
Also next year TNYA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.37%
EPS Next 3Y2.07%

0

5. Dividend

5.1 Amount

TNYA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

TENAYA THERAPEUTICS INC

NASDAQ:TNYA (11/4/2024, 8:00:00 PM)

After market: 2.43 +0.02 (+0.83%)

2.41

+0.47 (+24.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap190.12M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -73.99%
ROE -90.1%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 6.28
Quick Ratio 6.28
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)31.39%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y8.92%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y